Anticonvulsant | Low Risk

Brivaracetam (Briviact)

Brivaracetam risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Briviact.

Source: PBS, TGA Updated April 2026

Brivaracetam (brand names: Briviact) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Anticonvulsant with CNS depressant effects and potential for sedation affecting work capacity.

Key Takeaways

  • TGA Schedule: S4 in Australia
  • Risk level: Low (2 points)
  • CNS depressant: May cause sedation, impair driving, and affect work capacity
  • PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S4 PBS listed

Risk Profile

Risk Level Low
Risk Points 2
CNS Depressant Yes
Respiratory Risk No

Anticonvulsant with CNS depressant effects and potential for sedation affecting work capacity.

Regulatory and Compliance Guidance

When Brivaracetam appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.

Work capacity impact: As a CNS depressant, Brivaracetam may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.

Australia TGA / PBS / State Schemes

Classified as S4 under the Therapeutic Goods Administration (TGA).

Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.

Need to assess this medication across your caseload?

Run a full risk assessment including Brivaracetam interactions and compliance checks.

AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.

No credit card required. No signup for your first 2 questions.

Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.